Amphetamine Aspartate/Amphetamine Sulfate/Dextroamphetamine Saccharate/Dextroamphetamine Sulfate

CLEARWATER, Fla., May 15, 2025 /PRNewswire/ -- Dr. Todd M. Britten, a trusted periodontist in Clearwater, is raising awareness about a critical but often overlooked issue for patients taking medications for ADHD, depression, anxiety, and other psychiatric conditions – dry mouth, also known as xerostomia. This common side effect can lead to severe oral health complications, including periodontal disease, cavities, burning mouth syndrome, and oral thrush. Dr. Britten emphasizes the importance of understanding these risks and taking proactive steps to protect oral health while on these medications. Continue Reading View PDF The Connection Between Medications and Dry Mouth Many medications, particularly those prescribed for mental health conditions, are known to decrease saliva production. These medications include: Stimulants (e.g., Adderall), commonly used to treat ADHD, can cause dehydration and dry mouth. Antidepressants, such as SSRIs, tricyclics, and MAOIs, are linked to reduced saliva flow. Anxiety Medications, including benzodiazepines, have a drying effect on the mouth. Psychotropic Drugs, prescribed for conditions like schizophrenia and bipolar disorder, often lead to significant decreases in saliva production. Oral Health Complications Linked to Dry Mouth Saliva is essential for maintaining healthy teeth and gums. When its flow is reduced, it can contribute to several dental problems: Periodontal Disease: Reduced saliva creates an environment where bacteria can thrive, leading to gingivitis and periodontitis. Dental Caries (Cavities): The lack of saliva increases the risk of tooth decay, especially along the gumline and between teeth. Burning Mouth Syndrome: A burning sensation in the mouth can develop, particularly in those taking psychotropic medications. Candidiasis (Oral Thrush): Without enough saliva, fungal infections can become more common, causing discomfort and oral sores. Preventive Measures to Protect Oral Health To minimize the effects of dry mouth, Dr. Britten advises patients to implement the following strategies: Stay Hydrated: Drink plenty of water throughout the day to maintain moisture in the mouth. Use Saliva Substitutes: Artificial saliva products or sugar-free gum with xylitol can help stimulate saliva production. Maintain Good Oral Hygiene: Brush twice daily with fluoride toothpaste and floss regularly to reduce plaque buildup. Regular Dental Checkups: Schedule regular dental visits for professional cleanings and fluoride treatments. Avoid Alcohol and Caffeine: These substances can further dry out the mouth, so limiting consumption is recommended. Consult with Your Physician: If possible, work with your doctor to adjust medications or explore alternatives that may not have the same drying effects. Conclusion Dr. Todd M. Britten is urging patients who take medications that can cause dry mouth to take proactive steps in protecting their oral health. By understanding the risks and implementing preventive measures, patients can reduce the impact of dry mouth and maintain their oral hygiene. For those on long-term psychiatric medications, it's crucial to consult with both dental and medical professionals to ensure proper management of these side effects. About Dr. Todd M. Britten, DMD Dr. Todd M. Britten is a board-certified periodontist based in Clearwater, FL, specializing in advanced dental care and periodontal treatments. With a commitment to patient education and comprehensive care, Dr. Britten has helped countless patients maintain optimal oral health throughout their lives. SOURCE Todd M Britten, DMD, LLC. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

MAHWAH, N.J., April 16, 2025 /PRNewswire/ -- Glenmark Pharmaceuticals Inc., USA (Glenmark) is pleased to announce the upcoming launch[1] of Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product), 5 mg, 10 mg, 15 mg, 20 mg and 30 mg. Glenmark's Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product), 5 mg, 10 mg, 15 mg, 20 mg and 30 mg is bioequivalent and therapeutically equivalent to the reference listed drug, Adderall®[2] Tablets, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg, of Teva Women's Health, Inc. and the company will begin distribution in May 2025. According to IQVIA™ sales data for the 12-month period ending February 2025, the Adderall® Tablets, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg market[3] achieved annual sales of approximately $421.7 million*. Commenting on the launch, Marc Kikuchi, President & Business Head, North America, said, "Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product), 5 mg, 10 mg, 15 mg, 20 mg and 30 mg is a highly prescribed medication in the United States. Glenmark is very pleased to be able to help alleviate the shortage this country has been facing with this upcoming launch." About Glenmark Pharmaceuticals Ltd. Glenmark Pharmaceuticals Ltd. (BSE: 532296) (NSE: GLENMARK) is a research-led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of cardio-metabolic, respiratory, dermatology and oncology. The company has 11 world-class manufacturing facilities spread across 4 continents, and operations in over 80 countries. Scrip 100 positions Glenmark amongst the Top 100 biopharmaceutical companies ranked by Pharmaceutical Sales in 2023; while Generics Bulletin places it in the Top 50 Generics and biosimilar companies ranked by sales in 2024. Glenmark's Green House Gas (GHG) emission reduction targets have been approved in 2023 by the Science Based Target initiative (SBTi), making it only the second pharmaceutical company in India to achieve this. The organization has impacted over 3.3 million lives over the last decade through its CSR interventions. For more information, visit . You can follow us on LinkedIn (Glenmark Pharmaceuticals) and Instagram (glenmark_pharma). References: 1. Glenmark's Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product), 5 mg, 10 mg, 15 mg, 20 mg and 30 mg is only approved for the indication(s) listed in Glenmark's approved label. 2. All brand names and trademarks are the property of their respective owners. 3. Market includes brand and all available therapeutic equivalents. Note: IQVIA data obtained by Glenmark is only available for all approved RLD indications. Glenmark's product is only approved for the indications listed in Glenmark's approved label and is not marketed for all RLD indications. *IQVIA™ National Sales Perspectives: Retail & Non-Retail, February 2025. Logo: For more information, please contact: Udaykumar Murthy [email protected] +91 9960377617 SOURCE Glenmark Pharmaceuticals Ltd WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED